Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥75.0b (flat on FY 2023).
- Net income: CN¥2.84b (down 30% from FY 2023).
- Profit margin: 3.8% (down from 5.4% in FY 2023).
- EPS: CN¥1.74 (down from CN¥2.50 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Guangzhou Baiyunshan Pharmaceutical Holdings Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 21%.
Looking ahead, revenue is forecast to grow 3.7% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are up 1.7% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Guangzhou Baiyunshan Pharmaceutical Holdings has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.